Breast cancer is the most prevalent cancer in women and annually accounts for 10% of new malignancies worldwide ([@bib6]). In mainland China, ∼169 000 females are diagnosed with breast cancer every year and constitute 12.2% of the breast cancer incidents worldwide ([@bib7]). Additionally, 30% of early breast cancer turns metastatic, which is often incurable ([@bib18]). Different from women with early breast cancer, women with metastatic breast cancer (MBC) must receive lifelong treatment, experience higher levels of emotional/physical distress, and feel frequent uncertainty about their health/possible death ([@bib28]; [@bib27]). They are also challenged to manage distressing adverse effects induced by medical treatments and experience heavy self-care demands ([@bib24]; [@bib25]). Thus, specific interventions to help women with metastatic breast cancer to recover from this traumatic event have been designed, and one of these is supportive-expressive group therapy (SEGT).SEGT has been found to achieve improvement in anxiety, depression, quality of life (QoL), family functioning, and satisfaction with treatment ([@bib8]; [@bib20]; [@bib11]). However, the effect of SEGT on survival is inconsistent. Initial studies examining SEGT have reported a mean survival advantage of 18 months by [@bib21], however, these findings could not later be fully replicated in researches of [@bib4], [@bib13], [@bib8], and [@bib22]. Yet, no study has reported a survival disadvantage for those given SEGT ([@bib5]). In addition, we found no published articles on the application of SEGT among women with MBC in Mainland China. Owing to this dearth of previous research, it is unclear whether this therapy would exhibit positive effects within Chinese culture. Thus, we developed a 'Be Resilient to Breast Cancer' (BRBC) program that is culturally tailored for Chinese females with MBC. This program was adapted from SEGT and is designed to increase resilience (defined as the capacity to bounce back after encountering a traumatic event; [@bib2]; [@bib9]) and QoL, decrease emotional and physical distress (allostatic load), and eventually prolong longevity. In a multicenter randomised control trial of BRBC, based in Guangzhou, China, we examined 3- and 5-year cancer-specific survival as the primary outcome. The secondary outcomes were anxiety, depression, QoL, resilience, and Allostatic Load Index (ALI, a composite index measured by 14 indicators from different physiological systems),. We hypothesised that BRBC would (a) prolong 3- and 5-year survival, (b) decrease emotional distress (anxiety, depression, pain and so on) and physical distress (allostatic load), and (c) increase the resilience and QoL.

Materials and methods
=====================

Study protocol
--------------

Trial was conducted at First Affiliated Hospital of Guangzhou University of Chinese Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Sun Yat-sen University Cancer Center, and Affiliated Tumor Hospital of Guangzhou Medical University. Patients recruited from these hospitals all provided informed consent, and the study was approved by the ethics committees of all participating centers.

Patients were recruited between 2006 and 2011. Inclusion criteria were (1) women with confirmed MBC (2) metastases outside of the breast and ipsilateral axilla, and (3) fluent in oral Mandarin or Cantonese. Participants were excluded if they exhibited (1) central nervous system metastases, (2) a history of repeated suicidal behavior, (3) active psychosis or severe character disorder, (4) a life expectancy of \<3 months (as assessed by primary oncologist), and/or (5) declined to participate in the program. Potentially eligible women were scheduled for an in-office visit to complete consent forms and baseline biopsychosocial assessment (T1), and then were randomised by computer program to IG or CG.

The BRBC program consists of education and group discussion, and lasted for 12 months. To better adapt to Chinese culture, we added education hosted by professional staff (e.g., clinical psychologists, dietician, Chinese medicine practitioner and so on) in an effort to foster self-efficacy to combat symptoms (such as pain, fatigue, intrusive thoughts and so on) through knowledge and techniques (such as breath control, meditation and so on), and to help patients gain a sense of control in their life. Second, trained mentors, who were breast cancer survivors themselves, were added to the group discussion to create non-hierarchical, reciprocal relationships through the sharing of experiences with those facing similar challenges ([@bib29]; [@bib12]). Women in IG attended weekly sessions lasting for 120 min. Education took ∼45 min and covered a variety of topics related to breast cancer (e.g., radio-chemo treatment, depression, traditional Chinese medicine, Taichi, sexual issues, and so on (please see reference for further elaboration; [@bib32]). An outline covering all topics at each session was prepared by researchers as a template, to insure similar materials presented across centers. The group discussion followed the presentation and began with mentors sharing their experience with the topic (e.g., managing chemotherapy induced nausea), followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7--9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45--75 min. All leaders received a 4-day workshop before intervention, including Attention and Interpretation Therapy (AIT), which was designed to teach leaders to pay greater attention to positive things and helped cultivate skills (e.g., forgiveness, acceptance and so on). Leaders from different centers met monthly and discussed therapeutic principles in order to provide consistent intervention delivery. Participants were encouraged to attend as many of the sessions as possible and were considered as dropouts if they missed more than three consecutive sessions. Then, the project nurse would contact the patients, determine the reason for leaving, and encourage them to come back again.

Control group(CG) participants did not receive BRBC. However, a CD containing relaxation therapy (developed by the authors) was provided to every CG participant and monthly telephone follow-up was performed to prevent demoralisation from random assignment.

Randomisation
-------------

Stratified by centers, sealed envelopes with random numbers were applied to randomise participants. The sample size was set at 102 per group based on an expected five-year survival of 25% (CG) and 35% (IG). Ratio of assignment was IG:CG=1 : 1, assuming a two-tailed level of 0.05 and 80% power. These also predicted points of an effect size (ES) of 0.80 or greater. Additionally, 7--9 women were randomised to specific centers simultaneously at the beginning of the trial, in order to form an initial group at every center, with newly recruited patients randomised individually.

Masking
-------

Blinding was not designed in the parts of Randomisation. Data were collected by research assistants who were not involved in the design of trial and had no knowledge of participants treatment protocol.

Outcomes
--------

Primary outcome was 3- and 5-year cancer-specific survival. Secondary outcomes were anxiety, depression, QoL, resilience and ALI. Survival data were collected every 1--2 months till the end of the study. Secondary outcomes were only collected at baseline (T1), 2 months (T2), 6 months (T3), and 12 months (T4, after intervention).

Anxiety and depression were measured by the Chinese version of Hospital Anxiety and Depression Scale (HADS; [@bib14]), which contains 7 items for anxiety and 7 items for depression, respectively, scored on a 5-point scale. Higher scores indicate higher levels of anxiety and depression.

QoL was measured by QLQ-C30 core questionnaire of the European Organization for Research and Treatment of Cancer (EORTC; [@bib23]), which contains 30 items pertaining to different patient QoL aspects.

Resilience was measured by the 10 item Conner-Davison Resilience Scale (CD-RISC-10; [@bib3]), which is a self-administered questionnaire based on a 5-point scale, with higher scores reflecting more resilience.

ALI was a composite index measured by 14 indicators from different physiological systems, including body mass index (BMI), waist-hip ratio (WHR), resting pulse (RP), the standard deviation of R-R intervals (SDRR, heartbeat to heartbeat), resting systolic and diastolic blood pressure (SBP and DBP, respectively), white blood cell count (WBC), red blood cell count (RBC), hemoglobin, serotonin, hormone cortisol (HC), C-reactive protein (CRP), interleukin-6 (IL-6) and Cluster of Differentiation 4/Cluster of Differentiation 8(CD4^+^/CD8^+^). These indicators were selected to evaluate the functions of sympathetic nervous system (SNS), parasympathetic nervous system (PNS), hypothalamic pituitary adrenal (HPA), cardiovascular, inflammation, and immunisation. If a physical indicator was diagnosed as abnormal (i.e., RP of 107; normal range 60--100), patient would receive 1 point. Higher point totals indicated higher allostatic load. ALI range was from 0 (extremely low) to 14 (extremely high). These approaches to conceptualise physical allostatic load have been applied in previous studies ([@bib19]; [@bib10]; [@bib26]). All these data were collected when the patients came back to the hospital for a regular check. BMI, WHR, RP, SBP, and DBP were evaluated by their primary oncologist and SDRR was analysed by a cardiologist. The blood was drawn by the project nurse and biomakers were analysed in the clinical laboratory of the participating hospitals.

Data analysis
-------------

Baseline characteristics were examined by Pearson's *χ*^2^-test. Multivariate Cox proportional-hazards models were conducted to assess effects of BRBC on 3- and 5-year cancer-specific survival. Significant influencing factors were enrolled into the Cox model in order to reduce potential impact on the estimations of intervention effect. The main effects of the intervention between the two groups were compared by the ES and two-sample *t* test. Intent-to-treat analysis was performed at T2, T3, and T4. In addition, a Growth Mixture Model (GMM) was applied to determine the number of potential types of patients existing within groups over the 12-month period ([@bib17]). We hypothesised that more patients in IG would exhibit 'resilient' trajectories of psychosocial and physical outcomes (bounce back to normal in a short time) compared to CG. The bootstrapped likelihood ratio test (BLRT) and Bayesian information criteria (BIC) of the GMM were compared to determine the potential classes within the groups ([@bib16]). This approach was only applied to the indicators of anxiety, depression, QoL, and ALI, with resilience added as covariant. Missing data except for survival data and demographics was imputed by multiple imputation chained equations (MICE; [@bib31]). The imputation model included demographics, psychosocial outcomes and survival status ([@bib30]). The statistical significance was set at *P*=0.05 for all analyses. The software used were the SPSS version 17, STATA version 11, and MPLUS version 7.

Results
=======

Intervention and follow-up
--------------------------

Of 226 women who were enrolled into the study, 113 were randomly assigned to each group. However, 5 in IG and 9 in CG dropped out prior to intervention commencement. Main reason given for drop-outs was relocation. BRBC session attendance averaged 71.1% (28.4 of 40 possible per person-sessions) and showed no significant difference across centers. Primary reasons for nonattendance given were re-hospitalisation for medical treatment (24.3%), relocation (19.1%), busy (13.6%), and poor condition (17.4%). In addition, 9 of 108 women (8.3%) in IG and 13 of 104 women (12.5%) in CG reported attending support groups outside of the trial (*P*=0.3201). A total of 90.7% and 80.8% in the IG completed at least one follow-up for psychosocial scales and medical examination, respectively. The rate of completion in IG and CG was 72.1% and 62.5%, respectively. Rate did not differ significantly between groups (*P*=0.4288 for psychosocial scales; *P*=0.0853 for medical examination).

Sample characteristics
----------------------

During the 5-year follow-up, 13 participants (12.0%) dropped from IG and 19 (18.3%) from CG ([Figure 1](#fig1){ref-type="fig"}). No significant demographic differences between groups were observed, except for income (*P*=0.0254). Individuals lacking follow-ups were more likely to be minorities (*P*\<0.001 in IG, *P*=0.0440 in CG) and have a religious affiliation (*P*=0.0360 in IG, *P*\<0.001 in CG). Other characteristics between follow-ups and non-follow-ups could be found in [Table 1](#tbl1){ref-type="table"}.

Cancer-specific survival
------------------------

Median 5-year survival was 36.7 months (95% CI, 32.9--40.5) in IG and 31.5 months (95% CI, 28.8--35.9) in CG, according to Kaplan--Meier survival analysis ([Figure 2](#fig2){ref-type="fig"}). The Log Rank (Mantel-Cox) for 3-year survival (*χ*^2^=1.733, *P*=0.183) and 5-year survival (*χ*^2^=3.171, *P*=0.075) were not significant, and the hazard ratio (HR) for death in IG was 0.736 (95% CI, 0.525--1.133, *P*=0.076) compared with CG, based on univariate Cox model. Significant variables recognised by the Cox model were age (HR=1.406, 95% CI, 0.896--2.206, *P*=0.032), menopausal status (HR=0.648, 95% CI, 0.452--0.928, *P*=0.018), and oestrogen-receptor status (HR=1.474, 95% CI, 1.014--2.144, *P*=0.042). No significant effect of the BRBC program on 5-year survival (HR=0.837, 95% CI, 0.578--1.211, *P*=0.345) was identified after adjustment for significant risks in a multivariate Cox model.

Anxiety and depression
----------------------

At baseline, no difference was detected in psychological measures between groups (*P*=0.6985 for anxiety, *P*=0.3810 for depression, [Table 2](#tbl2){ref-type="table"}). Two months from start of intervention (T2), IG showed a significant reduction in both anxiety (ES=0.39, *P*=0.0226) and depression (ES=0.58, *P*=0.0024). At T3, the level of anxiety (ES=0.82, *P*\<0.0001) and depression (ES=0.87, *P*\<0.0001) were further decreased in IG. At T4, the level of anxiety (ES=0.85, *P*\<0.0001) and depression (ES=0.95, *P*\<0.0001) were quiet stable compared with T3 ([Table 3](#tbl3){ref-type="table"}). GMM recognised 4 potential classes of anxiety trajectories (BIC~min~=1782.89 for IG and BIC~min~=1813.22 for CG) and depression trajectories (BIC~min~=1694.23 for IG and BIC~min~=1712.45 for CG) respectively. These four specific trajectories ([Figure 3A--D](#fig3){ref-type="fig"}) were named as 'Chronic'(high and stable), 'Delayed'(from normal to high), 'Recovery'(from high to normal in a long time), and 'Resilient'(from normal to high and back to normal in a short time). More participants exhibited 'Resilient' types in IG than in CG on anxiety instead of depression (RR=2.06, 95% CI 1.08--3.91, *P*=0.0264 for anxiety; RR=1.59, 95% CI 0.82--3.11, *P*=0.1709 for depression).

QoL and resilience
------------------

QoL and resilience levels between groups did not differ significantly at baseline, except for dimension of nausea and vomiting (*P*=0.0119, [Table 2](#tbl2){ref-type="table"}). At T2, resilience level in IG increased (ES=0.31, *P*=0.0226). QoL (ES=0.35, *P*=0.0005) and its different dimensions (ES varied from 0.41--0.82, *P*\<0.05) in IG had also been improved, or less impaired compared with CG. In addition, some symptoms, (e.g., pain and fatigue) were reduced (ES varied from 0.29--0.65, *P*\<0.05).At T3, the difference of QoL (ES=−0.58, *P*\<0.0001), symptoms (ES varied from 0.53--0.79, *P*\<0.005), and resilience level (ES=−0.68, *P*\<0.0001) between groups were significant compared with T2. At T4, QoL (ES=−0.55, *P*\<0.0001) and resilience (ES=−0.67, *P*\<0.0001) in IG were stable compared to T3. GMM recognised 3 potential classes of QoL trajectories (BIC~min~=1853.64 for IG and BIC~min~=1926.74 for CG). These three specific trajectories ([Figure 3E and F](#fig3){ref-type="fig"}) were named as 'Impaired'(from high to low), 'Recovery'(from low to normal in long time), and 'Resilient' (from normal to low and back to normal in a short time) among groups. More IG participants were determined in 'Resilient' than in CG (RR=2.01, 95% CI 1.07--3.79, *P*=0.0290).

ALI
---

At baseline, the two groups did not show any significant difference in ALI (*P*=0.1817, [Table 2](#tbl2){ref-type="table"}). At T2, ALI had been improved, though the ES was not significant (ES=0.45, *P*=0.1345). From T2 to T4, ALI was much more enhanced (ES from 0.75--0.90). GMM recognised 4 potential classes of ALI trajectories (BIC~min~=1686.88 for IG and BIC~min~=1602.54 for CG). These three specific trajectories ([Figure 3G and H](#fig3){ref-type="fig"}) were named as 'Chronic' (high and stable), 'Delayed' (from normal to high), 'Recovery'(from high to normal in long time), and 'Resilient' (from normal to high and back to normal in a short time) among participants. There were more participants in IG determined in 'Resilient' than in CG (RR=2.70, 95% CI 1.42--5.13, *P*=0.0020).

Discussion
==========

The BRBC program failed to replicate the survival advantage in Chinese women with MBC. These findings are consistent with those of [@bib13] and [@bib8]. No significant difference in demographics were noted between groups, except for income, however, this influencing factor was not associated with the primary outcome. BRBC attendance was high (71.1%) and only nine women in IG lacked proper follow-ups (missed more than three consecutive sessions) through the first year. Therefore, poor group participation was not identified as a possible reason for missing an intervention effect. However, BRBC did alleviate emotional distress and enhance QoL, which were consistent with reports by [@bib11] and [@bib20]. The definition of resilience is debated ([@bib1]) and many researchers regard resilience as a personality trait which is hard to change while we hold that resilience is an ability that can be nurtured and enhanced after learning and training. The GMM analysis confirmed the ability hypothesis that more participants in IG presumably in 'Delayed' or 'Impaired' followed 'Resilient' trajectory (the emotional distress and physical distress of 'Delayed' or 'Impaired' return to normal in a short time after a elevation), which we believe indicated the BRBC program was effective and did enhance resilience levels. What's more, based on the result of reduced allostatic load in IG, the potential for psychosocial interventions to influence metastatic breast cancer survivals was also highlighted though the difference between IG and CG was not significant. However, these benefits may have been attributable to Taichi exercise (Ba Duan Jin) performed at the end of each group session. Participants in IG appreciated this light exercise and continued to engage in it post-treatment, which may have lowered neuroendocrine levels, mitigating inflammatory and metastatic processes, via stress response pathways ([@bib15]).

In order to recruit more mentors into our program to benefit more patients (we would like to make BRBC into a one-to-one mentorship program in the future), we conducted focus group interviews for every mentee who completed the program through the year. These interviews were designed to learn about expectations, satisfaction, gains, needs, difficulties, and suggestions for improving the BRBC program. After the interview, mentees were asked whether they would like to be mentors in the BRBC program. A total of 94 mentees were invited, of which, 33 (35.1%) were willing to be recruited and 27 (28.7%) were willing to do so in the next 2 years. Several themes emerged in the focus group interviews that help explain why Chinese women valued the BRBC program. Most important was that the program reduced stigma and increased a sense of belonging among participants. Some women who were antagonistic and sealing themselves off at the beginning, eventually opened up and became the 'big sister' in the group. The second theme was a sense of empowerment, especially an increase in confidence and hope. The participants used the techniques and knowledge learned from the sessions to combat physical and emotional distress, which increased their confidence and self-efficacy.

Some limitations should be considered. First, we did not insure that the psychological benefits of BRBC identified were representative, because we were unable to determine whether the participants willing to be enrolled were more (or less) distressed than the non-participants, as the collection of psychological information of non-participants was unethical. Second, BRBC was culturally tailored for Chinese females in the mainland. Thus, we cannot insure that this program can be generalised to other female groups with different cultural backgrounds. Third, though BRBC is based on the supportive-expressive program, it has been quite different from the original one due to additional components such as mentorship and education. Thus, the benefits of BRBC may not only be attributable to the supportive-expressive component and more researches to isolate the intervention effect of different components are warranted. Finally, we found that the survival difference between IG and CG had been increased from 3- to 5-year, according to univariate Cox model (*χ*^2^=1.733, *P*=0.183 for 3-year survival; *χ*^2^=3.171, *P*=0.075 for 5-year survival). Therefore, a longer follow-up may be needed to recognise the long term effects of BRBC on the survival of women with MBC.

In conclusion, this article reported a very successful project named Be Resilient to Breast Cancer (BRBC) with a sample of females with MBC and provided some latest progress of SEGT in Mainland China. BRBC does not improve survival of women with MBC in this study, though longer follow up is warranted. It does positively impact resilience, QoL, ALI, and emotional distress.
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![**Be Resilient to Breast Cancer trial accrual and retention.**](bjc2017325f1){#fig1}

![**Kaplan--Meier Survival Curves for women in IG and CG.** Black dotted line indicates a survival of 0.50 and 0.30 respectively.](bjc2017325f2){#fig2}

![**Growth Mixture Model (GMM) for secondary outcomes between IG and CG.** (**A**--**D**) Black dotted line indicates a sample of women without breast cancer from our previous study ([@bib32]). Red dotted line indicates a sample with high risk for anxiety and depression symptoms. (**E**--**H**) Black dotted line indicates a sample of women with non-metastatic breast cancer from our previous study ([@bib32]).](bjc2017325f3){#fig3}

###### Demographics and clinical variables of the participants

  **Variable No. (%)**               **The intervention group (IG,** ***n*****=95)**   **Loss of follow up (*****n*****=13)**   ***P*****-value**   **The control group (CG,** ***n*****=85)**   **Loss of follow up (*****n*****=19)**   ***P*****-value**   ***P*****-value (IG** ***vs*** **CG)**
  ---------------------------------- ------------------------------------------------- ---------------------------------------- ------------------- -------------------------------------------- ---------------------------------------- ------------------- ----------------------------------------
  Age                                                                                                                           0.0642                                                                                                    0.8675              0.4451
   ⩽40                               26 (27.4)                                         2 (15.4)                                                     24 (28.2)                                    5 (26.4)                                                      
   \>40 and ⩽60                      47 (49.5)                                         4 (30.8)                                                     35 (41.2)                                    7 (36.8)                                                      
   \>60                              22 (23.1)                                         7 (53.8)                                                     26 (30.6)                                    7 (36.8)                                                      
  Race                                                                                                                          \<0.001                                                                                                   0.0440              0.2831
   Han                               90 (94.7)                                         7 (53.8)                                                     77 (90.6)                                    14 (73.7)                                                     
   Other                             5 (5.3)                                           6 (46.2)                                                     8 (9.4)                                      5 (26.3)                                                      
  Education                                                                                                                     0.7481                                                                                                    0.5644              0.3185
   High school or lower              54 (56.8)                                         8 (61.5)                                                     42 (49.4)                                    8 (42.1)                                                      
   Undergraduate or higher           41 (43.2)                                         5 (38.5)                                                     43 (50.6)                                    11 (57.9)                                                     
  Income (monthly)                                                                                                              0.3828                                                                                                    0.5364              0.0254
   ⩽¥5000                            37 (38.9)                                         7 (53.8)                                                     34 (40.0)                                    8 (42.1)                                                      
   \>¥5000 and ⩽¥10 000              41 (43.2)                                         3 (23.1)                                                     23 (27.1)                                    7 (36.8)                                                      
   \>¥10 000                         17 (17.9)                                         3 (23.1)                                                     28 (32.9)                                    4 (21.1)                                                      
  Relationship                                                                                                                  \<0.001                                                                                                   0.1331              0.3200
   Single                            6 (6.3)                                           4 (30.8)                                                     9 (10.6)                                     2 (10.5)                                                      
   Married                           81 (85.3)                                         4 (30.8)                                                     65 (76.5)                                    11 (57.9)                                                     
   Divorced or widowed               8 (8.4)                                           5 (38.4)                                                     11 (12.9)                                    6 (31.6)                                                      
  Religious affiliation                                                                                                         0.0360                                                                                                    \<0.001             0.1335
   Yes                               19 (20.0)                                         6 (46.2)                                                     10 (11.8)                                    11 (57.9)                                                     
   No                                76 (80.0)                                         7 (53.8)                                                     75 (88.2)                                    8 (42.1)                                                      
  Employment                                                                                                                    0.1212                                                                                                    0.0528              0.1789
   Part/full time                    37 (38.9)                                         8 (61.5)                                                     25 (29.4)                                    10 (52.6)                                                     
   Unemployed                        58 (61.1)                                         5 (38.5)                                                     60 (70.6)                                    9 (47.4)                                                      
  Menopausal status                                                                                                             0.4873                                                                                                    0.4478              0.1030
   Premenopausal or perimenopausal   74 (77.9)                                         9 (69.2)                                                     57 (67.1)                                    11 (57.9)                                                     
   Postmenopausal                    21 (22.1)                                         4 (30.8)                                                     28 (32.9)                                    8 (42.1)                                                      
  Type of surgery                                                                                                               0.3617                                                                                                    0.0467              0.3843
   Mastectomy                        54 (56.8)                                         5 (38.5)                                                     42 (49.4)                                    7 (36.8)                                                      
   Lumpectomy                        32 (33.7)                                         7 (53.8)                                                     37 (43.5)                                    7 (36.8)                                                      
   Other                             9 (9.5)                                           1 (7.7)                                                      6 (7.1)                                      5 (26.4)                                                      
  Chemotherapy                                                                                                                  0.4285                                                                                                    0.4698              0.7540
   Ever                              59 (62.1)                                         5 (38.5)                                                     47 (49.5)                                    8 (42.1)                                                      
   Current                           67 (70.5)                                         9 (69.2)                                                     58 (68.2)                                    14 (73.7)                                                     
  Hormone therapy                                                                                                               0.9160                                                                                                    0.7539              0.7542
   Ever                              56 (58.9)                                         5 (38.5)                                                     54 (63.5)                                    12 (63.2)                                                     
   Current                           31 (32.6)                                         3 (23.1)                                                     27 (31.8)                                    5 (26.3)                                                      
  Radiation therapy                                                                                                             0.7484                                                                                                    0.3421              0.7737
   Ever                              40 (42.1)                                         5 (38.5)                                                     44 (51.8)                                    8 (42.1)                                                      
   Current                           12 (12.6)                                         2 (15.4)                                                     15 (17.6)                                    5 (26.3)                                                      
  Oestrogen-receptor status                                                                                                     0.2280                                                                                                    0.1208              0.3933
   Positive or equivocal             53 (55.8)                                         4 (30.8)                                                     53 (62.4)                                    7 (36.8)                                                      
   Negative                          31 (32.6)                                         7 (53.8)                                                     20 (23.5)                                    8 (42.1)                                                      
   Unknown                           11 (11.6)                                         2 (15.4)                                                     12 (14.1)                                    4 (21.1)                                                      
  Sites of metastases                                                                                                           0.0133                                                                                                    0.7913              0.4736
   Any visceral                      32 (33.7)                                         9 (69.2)                                                     33 (38.8)                                    8 (42.1)                                                      
   Nonvisceral only                  63 (66.3)                                         4 (30.8)                                                     52 (61.2)                                    11 (57.9)                                                     
  ECOG performance status                                                                                                       0.0098                                                                                                    0.0950              0.8105
   0                                 35 (36.8)                                         3 (23.1)                                                     35 (41.2)                                    8 (42.1)                                                      
   1                                 48 (50.5)                                         4 (30.7)                                                     39 (45.9)                                    5 (26.3)                                                      
   2                                 12 (12.6)                                         6 (46.2)                                                     11 (12.9)                                    6 (31.6)                                                      
  Estimated survival                                                                                                            0.8378                                                                                                    0.1448              0.9867
   6--12 months                      23 (24.2)                                         3 (23.0)                                                     21 (24.7)                                    7 (36.8)                                                      
   12--24 moths                      43 (45.3)                                         5 (38.5)                                                     39 (45.9)                                    4 (21.1)                                                      
   \>24 months                       29 (30.5)                                         5 (38.5)                                                     25 (29.4)                                    8 (42.1)                                                      

###### Descriptive statistics of the major variables at baseline (T1)

                 **IG (*****N*****=108)**   **CG (*****N*****=104)**                   
  ----- -------- -------------------------- -------------------------- ------- ------- --------
  AN     0--21   8.09                       2.78                       7.94    2.85    0.6985
  DE     0--21   10.32                      2.96                       9.96    3.01    0.3810
  QOL    0--100  60.49                      19.61                      57.63   18.34   0.2744
  PF     0--100  67.57                      22.69                      70.53   25.68   0.3744
  EF     0--100  45.68                      12.72                      48.67   15.28   0.1225
  RF     0--100  40.32                      12.21                      42.84   13.67   0.1580
  CF     0--100  49.64                      13.78                      47.63   16.39   0.3342
  SF     0--100  42.13                      14.45                      44.59   12.23   0.1831
  PA     0--100  62.48                      17.81                      65.24   18.25   0.2664
  FA     0--100  46.59                      15.37                      48.66   17.52   0.3610
  NV     0--100  34.65                      9.64                       31.37   9.16    0.0119
  IN     0--100  76.84                      24.69                      73.28   26.69   0.3143
  AL     0--100  68.64                      20.06                      69.63   17.84   0.7049
  RE     0--40   17.56                      6.08                       17.29   5.84    0.7421
  ALI    0--12   4.75                       1.43                       4.47    1.61    0.1817

Abbreviations: AL=appetite loss; ALI=Allostatic Load Index; AN=anxiety; CF=cognitive function; DE=depression; EF=emotional function; FA=fatigue; IN=insomnia; NV=nausea and vomit; PA=pain; PF=physical function; QOL=quality of life; RE=resilience; RF=role function; SF=social function.

###### Estimates of changes from baseline (T1) in major variables and their effect size among IG and CG at T2, T3, and T4

        **2-month change**   **6-month change**   **12-month change**                                                                           
  ----- -------------------- -------------------- --------------------- -------- -------- -------- ------- ---------- -------- -------- ------- ----------
  AN    1.12                 2.30                 0.39                  0.0226   0.35     2.92     0.82    \<0.0001   −0.33    2.21     0.85    \<0.0001
  DE    0.63                 2.62                 0.58                  0.0024   −0.74    2.20     0.87    \<0.0001   −1.40    1.58     0.95    \<0.0001
  QOL   −2.83                −9.35                −0.35                 0.0005   −1.88    −12.26   −0.58   \<0.0001   −5.13    −15.02   −0.55   \<0.0001
  PF    0.55                 −9.85                −0.45                 0.0173   −2.33    −13.64   −0.52   0.0024     −5.21    −15.87   −0.47   0.0154
  EF    6.63                 −6.16                −0.82                 0.0001   5.56     −8.41    −0.91   \<0.0001   7.54     −5.30    −0.92   \<0.0001
  RF    2.94                 −6.20                −0.69                 0.0008   4.95     −7.28    −0.94   \<0.0001   5.26     −7.16    −0.94   \<0.0001
  CF    3.25                 −3.49                −0.41                 0.0008   4.88     −7.38    −0.82   \<0.0001   3.38     −6.11    −0.63   \<0.0001
  SF    5.74                 −2.03                −0.53                 0.0226   10.03    −2.38    −0.82   0.0001     12.15    −0.21    −0.91   \<0.0001
  PA    −2.24                5.21                 0.37                  0.0018   −3.87    7.34     0.54    \<0.0001   −2.21    8.97     0.56    0.0001
  FA    −2.39                3.48                 0.36                  0.0004   −0.95    9.02     0.60    \<0.0001   1.64     9.68     0.47    0.0004
  NV    6.67                 13.89                0.65                  0.0295   7.40     16.37    0.79    0.0032     5.63     15.02    0.92    0.0006
  IN    −8.00                1.96                 0.41                  0.0555   −11.59   4.21     0.60    0.0025     −12.97   2.93     0.62    0.0026
  AL    −3.28                2.92                 0.29                  0.0311   −5.07    5.80     0.53    0.0002     −4.13    6.95     0.57    0.0002
  RE    1.56                 −0.45                −0.31                 0.0226   3.95     −0.27    −0.68   \<0.0001   4.68     0.38     −0.67   \<0.0001
  ALI   −0.22                0.49                 0.45                  0.1345   −0.46    0.67     0.75    0.0009     −0.64    0.78     0.90    \<0.0001

Abbreviations: AL=appetite loss; ALI=Allostatic Load Index; AN=anxiety; CF=cognitive function; DE=depression; EF=emotional function; ES=effect size; FA=fatigue; IN=insomnia; NV=nausea and vomit; PA=pain; PF=physical function; QOL=quality of life; RE=resilience; RF=role function; SF=social function.

Notes: a positive (negative) sign for the ES implies that the T2, T3, or T4 adjusted mean for Major Variables was lower (higher) for IG than CG.

[^1]: These authors contributed equally to this work and should be considered co-first authors.
